This article is more than 5 years old. Information may no longer be current.

TTT for CNV trial enrollment complete

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

MOUNTAIN VIEW, Calif. — Enrollment into a trial for transpupillary thermotherapy for the treatment of choroidal neovascularization has now been completed. The trial should be under way by mid-April, according to Iridex Corp., the company sponsoring the trial.

Dubbed the TTT4CNV trial, Iridex hopes to determine if transpupillary thermotherapy (TTT) can reduce the risk of vision loss for patients with occult wet age-related macular degeneration.

The TTT4CNV Clinical Trial is a multi-center, prospective, placebo-controlled, randomized trial conducted at 22 centers in the United States. The trial randomizes eyes with small (less than or equal to a 3-mm diameter) subfoveal occult choroidal neovascularization membranes and symptomatic vision loss (ETDRS visual acuity between 20/50 and 20/400). Eyes are treated using standardized treatment parameters, which will be compared to placebo-treated eyes. The trial is a post-marketing study, which is being performed within the Food and Drug Administration-cleared indications for the Iris Medical OcuLight SLx infrared laser system.